EMA Authorised: Rezzayo (rezafungin) — Mundipharma GmbH

View source ↗

Summary

The European Medicines Agency authorized Rezzayo (rezafungin) from Mundipharma GmbH for the treatment of candidiasis, including invasive candidiasis, with orpha…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Candidiasis
• Invasive Candidiasis

Drugs mentioned

• REZZAYO (REZAFUNGIN)

Snippet

Status: Authorised. Therapeutic area: Candidiasis;Candidiasis, Invasive. MAH: Mundipharma GmbH. Decision date: 07/04/2026. Orphan medicine